- Home
- INCY
INCY
Incyte Corp.
as 07-26-2024 4:00pm EST
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Upcoming Earnings Alert:
Get ready for potential market movements as Incyte Corp. INCY prepares to release earnings report on 30 Jul 2024.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 13.0B | IPO Year: | 1993 |
| Target Price: | $71.14 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.30 | EPS Growth: | 129.17 |
| 52 Week Low/High: | $50.27 - $70.36 | Next Earning Date: | 07-30-2024 |
| Revenue: | $3,767,865,000 | Revenue Growth: | 8.58% |
| Revenue Growth (this year): | 12.84% | Revenue Growth (next year): | 10.77% |
Stock Insider Trading Activity of Incyte Corp. (INCY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Flannelly Barry P | INCY | EVP & General Manager US | Jun 12 '24 | Sell | $60.00 | 19,164 | $1,149,840.00 | 66,377 | SEC Form 4 |
| Tray Thomas | INCY | Principal Accounting Officer | Jun 6 '24 | Sell | $58.91 | 1,093 | $64,388.63 | 21,634 | SEC Form 4 |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Jan 3 '24 | Sell | $65.51 | 7,365 | $482,481.15 | 90,218 | SEC Form 4 |
| Iyengar Vijay K | INCY | EVP, GMAPPS | Jan 2 '24 | Sell | $65.00 | 657 | $42,705.00 | 43,412 | SEC Form 4 |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 12 '23 | Sell | $57.36 | 210 | $12,045.60 | 24,503 | SEC Form 4 |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 12 '23 | Sell | $62.37 | 1,067 | $66,548.79 | 23,436 | SEC Form 4 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
MT Newswires
11 hours ago
Oppenheimer Adjusts Incyte Price Target to $81 From $84, Maintains Outperform Rating
Zacks
2 days ago
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
Zacks
2 days ago
Qiagen (QGEN) Expected to Beat Earnings Estimates: Should You Buy?
MT Newswires
2 days ago
Leerink Partners Adjusts Price Target on Incyte to $84 From $80
Zacks
3 days ago
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
7 days ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks
8 days ago
INCY or MYGN: Which Is the Better Value Stock Right Now?
Simply Wall St.
9 days ago
Is Incyte Corporation's (NASDAQ:INCY) Recent Stock Performance Tethered To Its Strong Fundamentals?
Compare INCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.